Quarterly revenue topped $1 billion, but BioMarin lowered its 2026 forecast for profit per share.
BioMarin reported Q3 2026 revenue of $1.025B, up 32% YoY, driven by GALAFOLD and POMBILITI + OPFOLDA. However, it lowered its 2026 EPS forecast due to order timing uncertainty and IPR&D charges. The company announced a new Fabry disease asset and FDA action dates for VOXZOGO. GAAP net loss increased to $31M, while non-GAAP income rose to $22M.
How this was made
The 30-second read
Why it matters
The guidance downgrade is a primary disclosure that can move the stock sharply, especially given the biotech sector's sensitivity to earnings forecasts.
Market read
Guidance cuts in biotech often trigger immediate sell pressure, affecting related stocks and sector sentiment.
What to watch
Acquisition synergies and pipeline progress could offset short‑term earnings pressure.
Background
BioMarin reported Q3 2026 revenue of $1.025B, highlighted new product launches and integration costs from recent acquisitions, and announced a lowered 2026 profit per share outlook.
Ticker impact
BioMarin lowered its 2026 profit per share forecast after reporting Q3 revenue above $1B but higher costs from acquisitions.
likely downside as investors price in lower profit expectations
Guidance revisions are material for biotech stocks and often trigger immediate price declines.
Market effects
May pressure other rare‑disease biotech peers as investors reassess guidance risk.
US biotech sector could see modest pullback.
Limited to biotech investors worldwide.
Counterpoint
If the revenue growth sustains, the profit forecast cut may be temporary and could present a buying opportunity.
Key entities
- companyBioMarin Pharmaceutical Inc.
US‑listed biotech company focusing on rare diseases.
